Help | RSS Feed



Ocuphire Pharma, Inc. (NASD:OCUP) Seasonal Chart

OCUP Relative to the S&P 500
OCUP Relative to the S&P 500

OCUP Relative to the Sector
OCUP Relative to the Sector

Monthly Seasonal Ocuphire Pharma, Inc. (NASD:OCUP)

Seasonal Chart Analysis

Analysis of the Ocuphire Pharma, Inc. (NASD:OCUP) seasonal charts above shows that a Buy Date of December 28 and a Sell Date of May 24 has resulted in a geometric average return of 39.98% above the benchmark rate of the S&P 500 Total Return Index over the past 16 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 16 years by an average of 56.87% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

To download OCUP seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z